Abstracts tagged "axial spondyloarthritis"

Abstract Number: 1507 • 2017 ACR/ARHP Annual Meeting
Comparison of the Clinical and Imaging Arms of the Assessment of Spondyloarthritis International Society Classification Criteria and Parameters of Objective Inflammation in Patients with Non-Radiographic Axial Spondyloarthritis
Robert B.M. Landewé¹, Joachim Sieper², Atul A. Deodhar³, Helena Marzo-Ortega⁴, Robert G. Lambert⁵, Mei Li⁶, Xin Wang⁶ and Jaclyn K. Anderson⁶, ¹University of Amsterdam, Amsterdam, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴NIHR LBRC, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, United Kingdom, ⁵University of Alberta, Edmonton, AB, Canada, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) recommendations for use of TNF inhibitors (TNFi) in axial SpA include active disease and a positive expert opinion,…
Abstract Number: 1513 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Atul A. Deodhar¹, Theresa Hunter², David Sandoval Calderon³, Steve Lobosco⁴, Rachel Moon⁴ and Gary Milligan⁵, ¹Oregon Health & Science University, Portland, OR, ²Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, IN, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Adelphi Real World, Macclesfield,, United Kingdom
Background/Purpose: Timely identification of nr-axSpA may lead to earlier intervention to reduce symptoms, improve function, and reduce disease burden. The purpose of this study was…
Abstract Number: 1515 • 2017 ACR/ARHP Annual Meeting
Improvements in Enthesitis Scores with Certolizumab Pegol Treatment in Males and Females with Active Axial Spondyloarthritis Are Maintained to Week 204
Maxime Dougados¹, Philip J Mease², Joachim Sieper³, Peter C. Taylor⁴, Natasha de Peyrecave⁵, Tommi Nurminen⁶ and Jürgen Braun⁷, ¹Rheumatology Department, Paris-Descartes University and Cochin Hospital, Paris, France, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Charité University Hospital, Berlin, Germany, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA), characterized by spinal inflammation, is also associated with extra-spinal manifestations including inflammation of the entheses (enthesitis). Enthesitis is equally prevalent throughout…
Abstract Number: 1566 • 2017 ACR/ARHP Annual Meeting
Elevated IL-1 Expression Levels in Mesenchymal Stem Cells Derived from Spondyloarthitis Patients Might be Linked to Increased Osteoblast Mineralization
Gerlinde Layh-Schmitt¹, Breanna Nguyen¹, Emily Lazowick¹, Stephen R. Brooks² and Robert Colbert¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIAMS/NIH, Biodata Mining & Discovery, Bethesda, MD
Background/Purpose: Axial spondyloarthritis (AxSpA) is an immune–mediated inflammatory disease involving the spine and sacroiliac joint. AxSpA is characterized by vertebral trabecular bone loss and progressive…
Abstract Number: 1573 • 2017 ACR/ARHP Annual Meeting
In Vivo Phosphorylation of p38 in Monocytes Is Enhanced in Patients with Axial Spondyloarthritis (axSpA) at the Time of Diagnosis
Antti Kuuliala^1,2, Krista Kuuliala^1,3, Riitta Koivuniemi^2,4, Mari Hämäläinen⁵, Eeva Moilanen⁶, Hannu Kautiainen⁷, Heikki Repo^1,3 and Marjatta Leirisalo-Repo^2,4, ¹Bacteriology and Immunology, University of Helsinki, Helsinki, Finland, ²Rheumatology, Helsinki University Hospital, Helsinki, Finland, ³Helsinki University Hospital, Helsinki, Finland, ⁴Rheumatology, University of Helsinki, Helsinki, Finland, ⁵The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, ⁶The Immunopharmacology Research Group, Faculty of Medicine and Life Sciences, University of Tampere and Tampere University Hospital, Tampere, Finland, Tampere, Finland, ⁷Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Host response to microbes is considered to contribute to the pathogenesis to axSpA and other HLA-B27 associated diseases. The p38 MAP kinase pathway plays…
Abstract Number: 1787 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis
Robert B.M. Landewé¹, Joachim Sieper², Philip J Mease³, Robert D Inman⁴, Xin Wang⁵, Mei Li⁵, Aileen L. Pangan⁵ and Jaclyn K. Anderson⁵, ¹University of Amsterdam, Amsterdam, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Department of Immunology, University of Toronto, Toronto, ON, Canada, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: It is not known whether TNF blockers can be stopped in non-radiographic (nr-axSpA) patients who are in remission. In ABILITY-1, adalimumab (ADA) significantly improved…
Abstract Number: 1831 • 2017 ACR/ARHP Annual Meeting
A Positive MRI of the Sacroiliac Joints Is Not Specific for Axial Spondyloarthritis but Frequently Occurs in Healthy Individuals
Janneke de Winter¹, Manouk de Hooge², Marleen van de Sande¹, Lonneke van Hoeven³, Jet de Jong¹, Anoek de Koning², Inger Jorid Berg⁴, Roberta Ramonda⁵, Dominique Baeten^1,6, Désirée van der Heijde⁷, Angelique Weel⁸ and Robert B.M. Landewé⁹, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁶UCB Pharma, Slough, United Kingdom, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁹Amsterdam Rheumatology & Immunology Center, Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Inflammation shown on MRI of the sacroiliac joint (MRI-SI) is prevalent in axSpA (±30%) but the specificity is not well known, hence we compared…
Abstract Number: 1877 • 2017 ACR/ARHP Annual Meeting
The Performance of MRI Using the 3D Volumetric Interpolated Breath-Hold Sequence (VIBE) Technique to Detect Structural Changes in Patients with Early Axial Spondyloarthritis in Comparison to Conventional Radiography and Computed Tomography
Xenofon Baraliakos¹, Florian Hoffmann¹, Xiaohu Deng², Yanyan Wang³, Feng Huang⁴ and Jürgen Braun⁵, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Chinese PLA General Hospital, Chinese PLA General Hospital, Beijing, China, ³Rheumatology, Chinese PLA General Hospital, Beijing, China, ⁴Chinese PLA General Hospital, Beijing, China, ⁵Institut für angewandte Statistik Dr. Jörg Schnitker GmbH, Bielefeld, Germany
Background/Purpose: Magnetic resonance imaging (MRI) is the gold standard for detection of inflammation in the sacroiliac joints (SIJ) of patients (pts) with axial spondyloarthritis (axSpA),…
Abstract Number: 2438 • 2017 ACR/ARHP Annual Meeting
Open Label Transitioning from Originator Etanercept to Biosimilar SB4 Compared to Continuing Treatment with Originator Etanercept in a Historical Cohort in Rheumatic Diseases in Daily Practice
L. Tweehuysen¹, V.J.B. Huiskes², B.J.F. Van den Bemt (PharmD, PhD)³, S. Teerenstra⁴, F.H.J. van den Hoogen⁵, C.H.M. van den Ende⁵ and A.A. Den Broeder⁵, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, ³Pharmacy, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands, ⁴Biostatistics, Radboudumc, Nijmegen, Netherlands, ⁵Rheumatology, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands
Background/Purpose: Blinded transitioning from originator infliximab (INX) to biosimilar CT-P13 was not inferior to continuing INX treatment.1 Open label mandatory transitioning resulted in a slightly…
Abstract Number: 733 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Non-Biological Therapy (Non-Biological Drugs and Non-Pharmacological Interventions): A Systematic Literature Review for the 2016 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis
Andrea Regel¹, Alexandre Sepriano², Xenofon Baraliakos¹, Désirée van der Heijde², Juergen Braun¹, Robert Landewé³, Filip van Den Bosch⁴ and Sofia Ramiro², ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology, Ghent University Hospital, Ghent, Belgium
Background/Purpose: As part of the 2016 update of the ASAS/EULAR recommendations for the management of axSpA, we performed a systematic literature review (SLR) to assess…
Abstract Number: 3037 • 2016 ACR/ARHP Annual Meeting
Calprotectin Is Highly Upregulated in Inflamed Axial Entheses in SKG Mice
Zheni Stavre¹, Yukiko Maeda² and Ellen M. Gravallese³, ¹Internal Medicine-Rheumatology, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, Worcester, MA, ³Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: SKG mice exhibit features of spondyloarthropathy (SpA) and inflammatory bowel disease (IBD). Their SpA-like phenotype is induced by a beta-glucan, curdlan, via the Dectin-1…
Abstract Number: 930 • 2016 ACR/ARHP Annual Meeting
How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁶, Glenn Haugeberg⁷ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Martina Hansens Hospital, Bærum, Norway
Background/Purpose: The EULAR recommendations for cardiovascular disease (CVD) risk management in patients with inflammatory joint diseases (IJD) states that CVD risk assessment should be considered…
Abstract Number: 3162 • 2016 ACR/ARHP Annual Meeting
Symmetric and Asymmetric Sacroiliitis Are Associated with Different Major Histocompatibility Class I Alleles in Psoriatic Arthritis
Jon T. Giles¹, Muhammad Haroon², Deepak R. Jadon³, Raj Sengupta⁴, Alison L Nightingale⁵, Eleanor Korendowych³, Jing Bi⁶, Neil J. McHugh³, Oliver FitzGerald⁷ and Robert Winchester⁶, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Kerry General Hospital, Co Kerry, Ireland, ³Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Rheumatology, Royal National Hospital for Rheumatic Diseases,, Bath, United Kingdom, ⁵Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁶Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁷St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland
Background/Purpose: HLA-B27 has been linked to sacroiliitis (SII) in psoriatic arthritis (PsA); however, the contribution to SII of other human leukocyte antigen (HLA) Class I…
Abstract Number: 1042 • 2016 ACR/ARHP Annual Meeting
Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Desiree van der Heijde¹, Xenofon Baraliakos², Kay-Geert Hermann³, Robert Landewé⁴, Pedro Machado⁵, Walter Maksymowych⁶, Owen Davies⁷, Natasha de Peyrecave⁷, Bengt Hoepken⁸, Lars Bauer⁸, Tommi Nurminen⁸ and Jürgen Braun⁹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumatology, Academic Medical Center, Amsterdam & Zuyderland Medical Center Heerlen, Amsterdam, Netherlands, ⁵Centre for Rheumatology Research & MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, ⁶Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: RAPID-axSpA (NCT01087762) was a long-term study in patients (pts) with axial spondyloarthritis (axSpA) treated with certolizumab pegol (CZP). This is the first report of…
Abstract Number: 1163 • 2016 ACR/ARHP Annual Meeting
Impact of E-Learning on Perceived Social Role Participation of Patients with Axial Spondyloarthritis: Results from a Longitudinal Randomized Control Trial
Daeria Lawson¹, Laura Passalent^2,3, Rita Kang⁴, Christopher Hawke^2,5, Ahmed Omar^6,7, Arane Thavaneswaran¹, Nigil Haroon^8,9 and Robert D Inman^6,10, ¹Toronto Western Hospital, Toronto, ON, Canada, ²Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ³Physical Therapy, University of Toronto, Toronto, ON, Canada, ⁴Patient and Family Education, Toronto Western Hospital, Toronto, ON, Canada, ⁵Department of Physical Therapy, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada, ⁸Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁹Medicine, Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁰University of Toronto, Toronto, ON, Canada
Background/Purpose: The purpose of this study was to Methods: Fifty-six adult patients with axSpA attending a tertiary academic spondyloarthritis clinic were randomly assigned to one…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].